<DOC>
	<DOCNO>NCT00311558</DOCNO>
	<brief_summary>RATIONALE : Sodium stibogluconate may stop growth cancer cell block enzymes need cell growth . Interferon may interfere growth cancer cell . Giving sodium stibogluconate together interferon may kill cancer cell . PURPOSE : This phase I trial study side effect best dose sodium stibogluconate give together interferon treat patient advance solid tumor , lymphoma , myeloma .</brief_summary>
	<brief_title>Sodium Stibogluconate Interferon Treating Patients With Advanced Solid Tumors , Lymphoma , Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Confirm tolerance , safety , maximum tolerate dose sodium stibogluconate ( SSG ) combination interferon alfa-2b patient advance solid tumor , lymphoma , myeloma . Secondary - Quantify effect SSG interferon alfa-2b-induced gene modulation signal transduction pathway measurement serum-soluble gene product β-2 microglobulin , immune serum globulin 15 , neopterin . - Define effectiveness SSG inhibit protein tyrosine phosphatase src homology protein ( SHP ) -1 SHP-2 assayed peripheral blood leukocytes patient receive SSG combination interferon alfa-2b . - Define pharmacokinetics SSG serum escalate dos . - Assess clinical response combination SSG interferon alfa-2b . OUTLINE : This open-label , dose-escalation study sodium stibogluconate ( SSG ) . Patients receive SSG IV 15 minute day 1 , 15-19 , 22-26 interferon alfa-2b subcutaneously daily day 8-12 15-28 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos SSG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antimony Sodium Gluconate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy , include , limited , follow : Renal cell carcinoma Melanoma Kaposi 's sarcoma Breast , prostate , colorectal , lung adenocarcinoma Bone soft tissue sarcoma Lymphoma Myeloma Tumors neuroendocrine endothelial cell origin Stage IV disease Refractory disease , resistant establish treatment , effective treatment available Measurable evaluable disease CNS metastases allow prior definitive therapy within past 3 month glucocorticoid require PATIENT CHARACTERISTICS : ECOG performance status 01 Granulocyte count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine &lt; 1.0 time upper limit normal ( ULN ) Creatinine clearance ≥ 60 mL/min Bilirubin &lt; 1.5 time ULN AST/ALT &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No history follow : Atrial fibrillation , atrial flutter , serious arrhythmia ( exclude asymptomatic atrial ventricular premature complex ) Congestive heart failure currently require treatment Angina pectoris Other severe cardiovascular disease ( i.e. , New York Heart Association class III IV heart disease ) No baseline ECG abnormality suggestive cardiac conduction delay , i.e. , 1° great atrioventricular block and/or complete incomplete ( QRS &gt; 120 m ) bundle branch block , repolarization abnormality ( i.e. , QTc ≥ 0.48 sec ) No systemic infection require antibiotic within past 14 day No know hepatitis B surface antigen positivity Psychologically prepare participate study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior interferon ( IFN ) therapy and/or ≤ 400 million unit IFN At least 3 week since prior major surgery At least 3 week since prior radiation therapy chemotherapy No prior solid organ allograft allogeneic bone marrow transplantation No concurrent daily glucocorticoid except physiological replacement No concurrent medication know prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>